JP2008538923A - ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法 - Google Patents

ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法 Download PDF

Info

Publication number
JP2008538923A
JP2008538923A JP2008509012A JP2008509012A JP2008538923A JP 2008538923 A JP2008538923 A JP 2008538923A JP 2008509012 A JP2008509012 A JP 2008509012A JP 2008509012 A JP2008509012 A JP 2008509012A JP 2008538923 A JP2008538923 A JP 2008538923A
Authority
JP
Japan
Prior art keywords
nicotinamide riboside
cell
nrk
seq
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008509012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538923A5 (https=
Inventor
ブレンナー,チャールズ,エム.
Original Assignee
トラスティーズ・オブ・ダートマウス・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トラスティーズ・オブ・ダートマウス・カレッジ filed Critical トラスティーズ・オブ・ダートマウス・カレッジ
Publication of JP2008538923A publication Critical patent/JP2008538923A/ja
Publication of JP2008538923A5 publication Critical patent/JP2008538923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2008509012A 2005-04-25 2006-04-20 ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法 Pending JP2008538923A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/113,701 US20050227327A1 (en) 2004-02-10 2005-04-25 Nicotinamide riboside kinase compositions and methods for using the same
PCT/US2006/015495 WO2006116322A2 (en) 2005-04-25 2006-04-20 Nicotinamide riboside kinase compositions and methods for using the same

Publications (2)

Publication Number Publication Date
JP2008538923A true JP2008538923A (ja) 2008-11-13
JP2008538923A5 JP2008538923A5 (https=) 2009-03-19

Family

ID=37215374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008509012A Pending JP2008538923A (ja) 2005-04-25 2006-04-20 ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法

Country Status (6)

Country Link
US (1) US20050227327A1 (https=)
EP (1) EP1877068A4 (https=)
JP (1) JP2008538923A (https=)
AU (1) AU2006238858B2 (https=)
CA (1) CA2609633C (https=)
WO (1) WO2006116322A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533308A (ja) * 2010-08-10 2013-08-22 ダミ ケミカル カンパニー リミテッド ニコチン酸アデニンディヌクレオチドリン酸又はその誘導体を含む薬学又は化粧料組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100047177A1 (en) * 2007-01-26 2010-02-25 Washington University Methods and compositions for treating neuropathies
CA2951287A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
WO2017004101A1 (en) * 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
KR102114892B1 (ko) 2016-01-11 2020-05-26 더 프록터 앤드 갬블 캄파니 피부 상태의 치료 방법 및 그를 위한 조성물
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
CN106755209B (zh) * 2016-12-29 2021-07-23 苏州汉酶生物技术有限公司 一种酶法制备β-烟酰胺单核苷酸的方法
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE
WO2019108873A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
KR20210011964A (ko) 2018-07-03 2021-02-02 더 프록터 앤드 갬블 캄파니 피부 병태를 치료하는 방법
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN115843238B (zh) 2020-06-01 2025-06-10 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521835A (ja) * 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1228222A2 (en) * 1999-11-04 2002-08-07 Incyte Genomics, Inc. Human transferase molecules
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521835A (ja) * 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533308A (ja) * 2010-08-10 2013-08-22 ダミ ケミカル カンパニー リミテッド ニコチン酸アデニンディヌクレオチドリン酸又はその誘導体を含む薬学又は化粧料組成物
US8816065B2 (en) 2010-08-10 2014-08-26 Damy Chemical Co., Ltd. Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof

Also Published As

Publication number Publication date
AU2006238858B2 (en) 2012-11-15
US20050227327A1 (en) 2005-10-13
AU2006238858A1 (en) 2006-11-02
EP1877068A2 (en) 2008-01-16
EP1877068A4 (en) 2009-01-21
WO2006116322A2 (en) 2006-11-02
WO2006116322A3 (en) 2008-01-17
CA2609633A1 (en) 2006-11-02
CA2609633C (en) 2015-12-01

Similar Documents

Publication Publication Date Title
US8383086B2 (en) Nicotinamide riboside kinase compositions and methods for using the same
CA2609633C (en) Nicotinamide riboside compositions
Mayeda et al. Purification and characterization of human RNPS1: a general activator of pre‐mRNA splicing
Watanabe et al. The first step of glycosylphosphatidylinositol biosynthesis is mediated by a complex of PIG‐A, PIG‐H, PIG‐C and GPI1
Gubser et al. A new inhibitor of apoptosis from vaccinia virus and eukaryotes
Ikeda et al. Purification and Characterization of Human NTH1, a Homolog ofEscherichia coli Endonuclease III: DIRECT IDENTIFICATION OF LYS-212 AS THE ACTIVE NUCLEOPHILIC RESIDUE
Schermer et al. Phosphorylation by casein kinase 2 induces PACS-1 binding of nephrocystin and targeting to cilia
Blanc et al. Ô‖ Identification of GRY-RBP as an Apolipoprotein B RNA-binding Protein That Interacts with Both Apobec-1 and Apobec-1 Complementation Factor to Modulate C to U Editing
Miller et al. Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype.
Agarwal et al. Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2−/− gene lipodystrophic mice
Zhang et al. Molecular cloning of the gene encoding nuclear DNA helicase II. A bovine homologue of human RNA helicase A and Drosophila Mle protein
Cen et al. Identification of UNC119 as a novel activator of SRC-type tyrosine kinases
Neumann et al. The death domain of IRAK-1: an oligomerization domain mediating interactions with MyD88, Tollip, IRAK-1, and IRAK-4
Chauhan et al. Glyoxalase I gene deletion mutants of Leishmania donovani exhibit reduced methylglyoxal detoxification
JPH09509319A (ja) Rna修正酵素およびその使用方法
CA2568201C (en) Identification of ergothioneine transporter and therapeutic uses thereof
JP2016507522A (ja) ミトコンドリア疾患及び神経変性疾患を処置するための方法
CN100390286C (zh) 新酶基因及其表达产物
US20050014692A1 (en) Lactate dehydrogenase as a novel target and reagent for diabetes therapy
CN113227788A (zh) 一种辅助诊断和治疗帕金森病的方法和试剂
JP4674332B2 (ja) Txk複合体およびその利用
Armistead Role of EMG1 in Bowen-Conradi syndrome and in ribosome biogenesis
KALDOR actomyosin of aging rats1, 2
Gietzen The identification and characterization of casein kinase I epsilon
Lopez-Berestein et al. Method of identifying inhibitors of glutathione S-transferase (GST) gene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120522